← ALL REGULATORY INTELLIGENCEKNOWLEDGE / REGULATORY DEVELOPMENTS
DRAP5 November 2026 — official sourceRapid Alert I/S/11-05-50

DRAP Rapid Alert 50 identifies nine adulterated, spurious or unregistered medicinal products

Product-specific rapid alertRapid Alert I/S/11-05-50

DRAP's 5 November rapid alert reports laboratory findings concerning nine named ophthalmic, mouthwash, lotion and ear-cream products; legal classifications differ by product.

DRAP's 5 November rapid alert reports laboratory findings concerning nine named ophthalmic, mouthwash, lotion and ear-cream products; legal classifications differ by product.

01 / REGULATORY ANALYSIS

The named products

Rapid Alert I/S/11-05-50 concerns Baby Eye Spray (tobramycin), Tobramycin Ophthalmic Solution, Total Care Mouthwash, Magic Lotion (calamine), Denzicor Mouth Wash, Anti Plaque Mouth Wash, Happy Tooth Kids Mouthwash, Baby Care Ear Cream and Vital Ear Cream. The laboratory identified Magic Lotion batch 002; the alert does not give batch numbers for the other listed products.

Sindh's Drug Testing Laboratory in Karachi reported findings variously described as adulterated, substandard, spurious and/or unregistered. The precise remarks against each item are set out in the original DRAP table and should not be indiscriminately applied to every product.

02 / REGULATORY ANALYSIS

Regulatory response

DRAP states that provincial drug-control field teams have been asked to conduct surveillance across the supply chain and confiscate affected falsified products. DRAP advises healthcare professionals to maintain vigilance in pharmacies and healthcare facilities.

The notice is a product-specific quality and enforcement communication, not a wholesale finding against every product manufactured by a business named in the table.

03 / REGULATORY ANALYSIS

Compliance for healthcare suppliers

Pharmacies, hospitals, importers and distributors should compare inventory, supplier and batch data with the complete official list, isolate suspected stock pending verification and preserve procurement records. Any adverse events or quality issues should be reported through the pharmacovigilance process.

DRAP advises consumers not to use the identified products and to contact healthcare professionals if they have been affected.

04 / REGULATORY ANALYSIS

Limits of the findings

Do not extend this notice to unlisted batches or unrelated medicines without evidence. The official manufacturer, packaging, product and batch descriptions take priority over abbreviated market names.

Related reading

For other notices, decisions and regulatory developments, see the Regulatory Intelligence archive. This report does not treat a proposed measure or operational notice as enacted law.

OFFICIAL SOURCERapid Alert I/S/11-05-50

Drug Regulatory Authority of Pakistan — 5 November 2026

READ SOURCE ↗